Dionysia Kefala has graduated from University of Thessaly with a BSc degree in Biochemistry and Biotechnology. Following her graduation, she pursued a MSc degree in Oncology at Vrije University of Amsterdam. During her MSc studies she was enrolled in research projects with CAR-T cells against multiple myeloma at Vumc Cancer Center at the Department of Hematology under the guidance of Maria Themeli and with CRISPR-Cas-edited iPSCs for AML modeling at the iPSCs Core Facility of the University of Nantes under the supervision of Laurent David.
Currently, she is enrolled in a PhD program at the Bone Marrow Transplantation Lab, School of Medicine, University of Patras working on the pre-clinical development of a GMP-compatible protocol for the production of a T cell immunotherapy with inducible HLAG+ Regulatory T Cells (iG-Tregs) against GvHD after allo-HSCT (funded by H.R.F.I, 2020-2023). This immunotherapy is going to be evaluated in a Phase I/II Study in patients undergoing HLA-matched sibling donor allogeneic haematopoietic stem cell transplantation (EudraCT 2021-006367-26). Dionysia is also preparing the investigational new drug submission to the Greek Organization of Medicines as well as the GMP-required documents for the iG-Tregs production in the GMP Facility of Institute of Cell Therapy of Research Center of Patras.